UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies

Journal of cellular and molecular medicine, 2016-07, Vol.20 (7), p.1287-1294

2016

Volltextzugriff (PDF)

Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models

Pharmaceutical research, 2018-06, Vol.35 (6), p.118-10, Article 118

2018

Volltextzugriff (PDF)

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Journal of hematology and oncology, 2017-01, Vol.10 (1), p.13-13, Article 13

2017

Volltextzugriff (PDF)

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

Cancer Immunology, Immunotherapy, 2008-03, Vol.57 (3), p.411-423

2008

Volltextzugriff (PDF)

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

Clinical cancer research, 2009-06, Vol.15 (12), p.4028-4037

2009

Volltextzugriff (PDF)

Retargeting of natural killer–cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction

Blood, 2002-08, Vol.100 (4), p.1265-1273

2002

Volltextzugriff (PDF)

DNA-carrier proteins for targeted gene delivery

Advanced drug delivery reviews, 2000-11, Vol.44 (2), p.153-166

2000

Volltextzugriff (PDF)

A Modular DNA Carrier Protein Based on the Structure of Diphtheria Toxin Mediates Target Cell-specific Gene Delivery

The Journal of biological chemistry, 1998-04, Vol.273 (15), p.8835-8841

1998

Volltextzugriff (PDF)

NK cells engineered to express a GD 2 ‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin

Journal of cellular and molecular medicine, 2012-03, Vol.16 (3), p.569-581

2012

Volltextzugriff (PDF)

NK cells engineered to express a GD2‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin

Journal of cellular and molecular medicine, 2012-03, Vol.16 (3), p.569-581

2012

Volltextzugriff (PDF)

In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging

European radiology, 2005-01, Vol.15 (1), p.4-13

2005

Volltextzugriff (PDF)

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway

Immunology and cell biology, 2015-04, Vol.93 (4), p.396-405

2015

Volltextzugriff (PDF)

CD 19‐ CAR engineered NK ‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies

Journal of cellular and molecular medicine, 2016-07, Vol.20 (7), p.1287-1294

2016

Volltextzugriff (PDF)

Tracking of [18 F]FDG-labeled natural killer cells to HER2/neu-positive tumors

Nuclear medicine and biology, 2008-07, Vol.35 (5), p.579-588

2008

Volltextzugriff (PDF)

BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib

Blood, 2010-11, Vol.116 (21), p.3008-3008

2010

Volltextzugriff (PDF)

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Blood, 2010-11, Vol.116 (21), p.3060-3060

2010

Volltextzugriff (PDF)

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Blood, 2011-11, Vol.118 (21), p.305-305

2011

Volltextzugriff (PDF)

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Blood, 2009-11, Vol.114 (22), p.1862-1862

2009

Volltextzugriff (PDF)

DNA-carrier proteins for targeted gene delivery: Challenges of Turning Nucleic Acids into Therapeutics

Advanced drug delivery reviews, 2000, Vol.44 (2-3), p.153-166

2000

Volltextzugriff (PDF)

Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors

Cancer Immunology, Immunotherapy, 2004-03, Vol.53 (3), p.217-226

2004

Volltextzugriff (PDF)

Re-Targeting of an NK Cell Line (NK92) with Specificity for CD19 Efficiently Kills Human B-Precursor Leukemia Cells

Blood, 2004-11, Vol.104 (11), p.2747-2747

2004

Volltextzugriff (PDF)

CD31/PECAM-1 is a ligand for alphavbeta3 integrin involved in adhesion of leukocytes to endothelium

The Journal of cell biology, 1995-07, Vol.130 (2), p.451

1995

Volltextzugriff (PDF)

CD31/PECAM-1 Is a Ligand for α vβ 3 Integrin Involved in Adhesion of Leukocytes to Endothelium

The Journal of cell biology, 1995-07, Vol.130 (2), p.451-460

1995

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies

Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

Retargeting of natural killer–cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction

DNA-carrier proteins for targeted gene delivery

A Modular DNA Carrier Protein Based on the Structure of Diphtheria Toxin Mediates Target Cell-specific Gene Delivery

NK cells engineered to express a GD 2 ‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin

NK cells engineered to express a GD2‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin

In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway

CD 19‐ CAR engineered NK ‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies

Tracking of [18 F]FDG-labeled natural killer cells to HER2/neu-positive tumors

BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

DNA-carrier proteins for targeted gene delivery: Challenges of Turning Nucleic Acids into Therapeutics

Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo

Re-Targeting of an NK Cell Line (NK92) with Specificity for CD19 Efficiently Kills Human B-Precursor Leukemia Cells

The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo

CD31/PECAM-1 is a ligand for alphavbeta3 integrin involved in adhesion of leukocytes to endothelium

CD31/PECAM-1 Is a Ligand for α vβ 3 Integrin Involved in Adhesion of Leukocytes to Endothelium

Suchergebnisse filtern